The EDGE

You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia

A R Sehgal, H Konig, D E Johnson, D Tang, R K Amaravadi, M Boyiadzis and M T Lotze

Leukemia 2015 29: 517-525; advance online publication, November 26, 2014; 10.1038/leu.2014.349

Original Articles

ACUTE LEUKEMIAS

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia OPEN

D J DeAngelo, K E Stevenson, S E Dahlberg, L B Silverman, S Couban, J G Supko, P C Amrein, K K Ballen, M D Seftel, A R Turner, B Leber, K Howson-Jan, K Kelly, S Cohen, J H Matthews, L Savoie, M Wadleigh, L A Sirulnik, I Galinsky, D S Neuberg, S E Sallan and R M Stone

Leukemia 2015 29: 526-534; advance online publication, July 31, 2014; 10.1038/leu.2014.229

NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia

D Gerloff, R Grundler, A A Wurm, D Bräuer-Hartmann, C Katzerke, J-U Hartmann, V Madan, C Müller-Tidow, J Duyster, D G Tenen, D Niederwieser and G Behre

Leukemia 2015 29: 535-547; advance online publication, August 5, 2014; 10.1038/leu.2014.231

Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study

L S G Østgård, J M Nørgaard, H Sengeløv, M Severinsen, L S Friis, C W Marcher, I H Dufva and M Nørgaard

Leukemia 2015 29: 548-555; advance online publication, August 5, 2014; 10.1038/leu.2014.234

Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model

P Yu, M N Petrus, W Ju, M Zhang, K C Conlon, M Nakagawa, M Maeda, R N Bamford and T A Waldmann

Leukemia 2015 29: 556-566; advance online publication, August 14, 2014; 10.1038/leu.2014.241

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia

C Niederwieser, J Kohlschmidt, S Volinia, S P Whitman, K H Metzeler, A-K Eisfeld, K Maharry, P Yan, D Frankhouser, H Becker, S Schwind, A J Carroll, D Nicolet, J H Mendler, J P Curfman, Y-Z Wu, M R Baer, B L Powell, J E Kolitz, J O Moore, T H Carter, R Bundschuh, R A Larson, R M Stone, K Mrózek, G Marcucci and C D Bloomfield

Leukemia 2015 29: 567-575; advance online publication, September 10, 2014; 10.1038/leu.2014.267

Hes1 suppresses acute myeloid leukemia development through FLT3 repression

T Kato, M Sakata-Yanagimoto, H Nishikii, M Ueno, Y Miyake, Y Yokoyama, Y Asabe, Y Kamada, H Muto, N Obara, K Suzukawa, Y Hasegawa, I Kitabayashi, K Uchida, A Hirao, H Yagita, R Kageyama and S Chiba

Leukemia 2015 29: 576-585; advance online publication, September 19, 2014; 10.1038/leu.2014.281

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

A M Eiring, B D G Page, I L Kraft, C C Mason, N A Vellore, D Resetca, M S Zabriskie, T Y Zhang, J S Khorashad, A J Engar, K R Reynolds, D J Anderson, A Senina, A D Pomicter, C C Arpin, S Ahmad, W L Heaton, S K Tantravahi, A Todic, R Colaguori, R Moriggl, D J Wilson, R Baron, T O'Hare, P T Gunning and M W Deininger

Leukemia 2015 29: 586-597; advance online publication, August 19, 2014; 10.1038/leu.2014.245

CHRONIC LYMPHOCYTIC LEUKEMIA

A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact

A C Queirós, N Villamor, G Clot, A Martinez-Trillos, M Kulis, A Navarro, E M M Penas, S Jayne, A Majid, J Richter, A K Bergmann, J Kolarova, C Royo, N Russiñol, G Castellano, M Pinyol, S Bea, I Salaverria, M López-Guerra, D Colomer, M Aymerich, M Rozman, J Delgado, E Giné, M González-Díaz, X S Puente, R Siebert, M J S Dyer, C López-Otín, C Rozman, E Campo, A López-Guillermo and J I Martín-Subero

Leukemia 2015 29: 598-605; advance online publication, August 25, 2014; 10.1038/leu.2014.252

STEM CELLS

In vitro expansion of CD34⁺CD38⁻ cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia

K Sakashita, I Kato, T Daifu, S Saida, H Hiramatsu, Y Nishinaka, Y Ebihara, F Ma, K Matsuda, S Saito, K Hirabayashi, T Kurata, L T N Uyen, Y Nakazawa, K Tsuji, T Heike, T Nakahata and K Koike

Leukemia 2015 29: 606-614; advance online publication, August 8, 2014; 10.1038/leu.2014.239

FHL2 regulates hematopoietic stem cell functions under stress conditions

Y Hou, X Wang, L Li, R Fan, J Chen, T Zhu, W Li, Y Jiang, N Mittal, W Wu, D Peace and Z Qian

Leukemia 2015 29: 615-624; advance online publication, September 2, 2014; 10.1038/leu.2014.254

CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia

P M Korthuis, G Berger, B Bakker, M Rozenveld-Geugien, J Jaques, G de Haan, J J Schuringa, E Vellenga and H Schepers

Leukemia 2015 29: 625-635; advance online publication, September 3, 2014; 10.1038/leu.2014.259

IMMUNOLOGY

Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10

Y Peng, X Chen, Q Liu, X Zhang, K Huang, L Liu, H Li, M Zhou, F Huang, Z Fan, J Sun, Q Liu, M Ke, X Li, Q Zhang and A P Xiang

Leukemia 2015 29: 636-646; advance online publication, July 18, 2014; 10.1038/leu.2014.225

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

C Berlin, D J Kowalewski, H Schuster, N Mirza, S Walz, M Handel, B Schmid-Horch, H R Salih, L Kanz, H-G Rammensee, S Stevanović and J S Stickel

Leukemia 2015 29: 647-659; advance online publication, August 5, 2014; 10.1038/leu.2014.233

SENSITIVITY AND RESISTANCE TO THERAPY

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups

M-T Krauth, T Alpermann, U Bacher, C Eder, F Dicker, M Ulke, S Kuznia, N Nadarajah, W Kern, C Haferlach, T Haferlach and S Schnittger

Leukemia 2015 29: 660-667; advance online publication, August 11, 2014; 10.1038/leu.2014.243

LYMPHOMA

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study

H R Junlén, S Peterson, E Kimby, S Lockmer, O Lindén, H Nilsson-Ehle, M Erlanson, H Hagberg, A Rådlund, O Hagberg and B E Wahlin

Leukemia 2015 29: 668-676; advance online publication, August 25, 2014; 10.1038/leu.2014.251

The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing

I Vater, M Montesinos-Rongen, M Schlesner, A Haake, F Purschke, R Sprute, N Mettenmeyer, I Nazzal, I Nagel, J Gutwein, J Richter, I Buchhalter, R B Russell, O D Wiestler, R Eils, M Deckert and R Siebert

Leukemia 2015 29: 677-685; advance online publication, September 5, 2014; 10.1038/leu.2014.264

Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party

A Tanase, N Schmitz, H Stein, A Boumendil, H Finel, L Castagna, D Blaise, N Milpied, G Sucak, A Sureda, K Thomson, E Vandenberghe, A Vitek and P Dreger on behalf of the Lymphoma Working Party of the EBMT

Leukemia 2015 29: 686-688; advance online publication, September 19, 2014; 10.1038/leu.2014.280

MYELOMA

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

S Ferrero, M Ladetto, D Drandi, F Cavallo, E Genuardi, M Urbano, S Caltagirone, M Grasso, F Rossini, T Guglielmelli, C Cangialosi, A M Liberati, V Callea, T Carovita, C Crippa, L De Rosa, F Pisani, A P Falcone, P Pregno, S Oliva, C Terragna, P Musto, R Passera, M Boccadoro and A Palumbo

Leukemia 2015 29: 689-695; advance online publication, July 16, 2014; 10.1038/leu.2014.219

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma

J S Waizenegger, I Ben-Batalla, N Weinhold, T Meissner, M Wroblewski, M Janning, K Riecken, M Binder, D Atanackovic, H Taipaleenmaeki, D Schewe, S Sawall, V Gensch, M Cubas-Cordova, A Seckinger, W Fiedler, E Hesse, N Kröger, B Fehse, D Hose, B Klein, M S Raab, K Pantel, C Bokemeyer and S Loges

Leukemia 2015 29: 696-704; advance online publication, August 8, 2014; 10.1038/leu.2014.236

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

E M Ocio, D Fernández-Lázaro, L San-Segundo, L López-Corral, L A Corchete, N C Gutiérrez, M Garayoa, T Paíno, A García-Gómez, M Delgado, J C Montero, E Díaz-Rodríguez, M V Mateos, A Pandiella, S Couto, M Wang, C C Bjorklund and J F San-Miguel

Leukemia 2015 29: 705-714; advance online publication, August 8, 2014; 10.1038/leu.2014.238

Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma

Y Yang, Y Chen, M N Saha, J Chen, K Evans, L Qiu, D Reece, G A Chen and H Chang

Leukemia 2015 29: 715-726; advance online publication, September 2, 2014; 10.1038/leu.2014.255

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib OPEN

S Jagannathan, N Vad, S Vallabhapurapu, S Vallabhapurapu, K C Anderson and J J Driscoll

Leukemia 2015 29: 727-738; advance online publication, September 19, 2014; 10.1038/leu.2014.279

Letters to the Editor

Ruxolitinib and survival improvement in patients with myelofibrosis

F Passamonti, A M Vannucchi, F Cervantes, C Harrison, E Morra, H Kantarjian and S Verstovsek

Leukemia 2015 29: 739-740; advance online publication, September 24, 2014; 10.1038/leu.2014.282

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis

G Barosi and R P Gale

Leukemia 2015 29: 740; advance online publication, November 3, 2014; 10.1038/leu.2014.312

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis OPEN

A Pardanani, R A Abdelrahman, C Finke, T T Lasho, K H Begna, A Al-Kali, W J Hogan, M R Litzow, C A Hanson, R P Ketterling and A Tefferi

Leukemia 2015 29: 741-744; advance online publication, November 11, 2014; 10.1038/leu.2014.306

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition OPEN

C Pepper, A G S Buggins, C H Jones, E J Walsby, F Forconi, G Pratt, S Devereux, F K Stevenson and C Fegan

Leukemia 2015 29: 744-747; advance online publication, October 28, 2014; 10.1038/leu.2014.308

Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk OPEN

G P Sava, H E Speedy, M C Di Bernardo, M J S Dyer, A Holroyd, N J Sunter, H Marr, L Mansouri, S Deaglio, L Karabon, I Frydecka, K Jamroziak, D Woszczyk, G Juliusson, K E Smedby, S Jayne, A Majid, Y Wang, C Dearden, A G Hall, T Mainou-Fowler, G H Jackson, G Summerfield, R J Harris, A R Pettitt, D J Allsup, J R Bailey, G Pratt, C Pepper, C Fegan, R Rosenquist, D Catovsky, J M Allan and R S Houlston

Leukemia 2015 29: 748-751; advance online publication, November 3, 2014; 10.1038/leu.2014.311

Classifying ultra-high risk smoldering myeloma

A J Waxman, R Mick, A L Garfall, A Cohen, D T Vogl, E A Stadtmauer and B M Weiss

Leukemia 2015 29: 751-753; advance online publication, November 5, 2014; 10.1038/leu.2014.313

Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis

C Q Wang, D W L Chin, J Y Chooi, W J Chng, I Taniuchi, V Tergaonkar and M Osato

Leukemia 2015 29: 753-757; advance online publication, November 5, 2014; 10.1038/leu.2014.316

Corrigendum

Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis

L Bassaganyas, S Beà, G Escaramís, C Tornador, I Salaverria, L Zapata, O Drechsel, P G Ferreira, B Rodriguez-Santiago, J M C Tubio, A Navarro, D Martín-García, C López, A Martínez-Trillos, A López-Guillermo, M Gut, S Ossowski, C López-Otín, E Campo and X Estivill

Leukemia 2015 29: 758; 10.1038/leu.2014.309